Condition: Testicular Cancer · Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
The aim of this study is to evaluate the oncologic and functional outcomes of RPLND as primary treatment (stage I and IIA-IIB with negative markers) or of residual masses after chemotherapy (PC-RPLND) in the treatment of patients with seminomatous and non-seminomatous. In order to evaluate the role and the͛clinical impact of different surgical techniques of RPLND will be included patients treated with open, laparoscopic, and robot-assisted techniques
This description comes directly from the study's public registry record.
Angelo Mottaran, MD · +39 3398946529 · angelo.mottaran2@unibo.it
Always discuss trial participation with your own doctor first.
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | Bologna, Bologna, Italy | Recruiting |
| UO di Chirurgia Urologica della Fondazione IRCCS Istituto Nazionale dei Tumori di Milano | Milan, Italy, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06806917